Literature DB >> 32611579

Reply to Aron P. Kater et al.

Riccardo Moia1, Gianluca Gaidano1, Davide Rossi2.   

Abstract

Year:  2020        PMID: 32611579      PMCID: PMC7327660          DOI: 10.3324/haematol.2020.255596

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

Review 1.  Biomarker: Predictive or Prognostic?

Authors:  Karla V Ballman
Journal:  J Clin Oncol       Date:  2015-09-21       Impact factor: 44.544

2.  Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Authors:  Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Weiqiang Zhao; Allison M Booth; Wei Ding; Nancy L Bartlett; Danielle M Brander; Paul M Barr; Kerry A Rogers; Sameer A Parikh; Steven Coutre; Arti Hurria; Jennifer R Brown; Gerard Lozanski; James S Blachly; Hatice G Ozer; Brittny Major-Elechi; Briant Fruth; Sreenivasa Nattam; Richard A Larson; Harry Erba; Mark Litzow; Carolyn Owen; Charles Kuzma; Jeremy S Abramson; Richard F Little; Scott E Smith; Richard M Stone; Sumithra J Mandrekar; John C Byrd
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

3.  Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Authors:  Tait D Shanafelt; Xin V Wang; Neil E Kay; Curtis A Hanson; Susan O'Brien; Jacqueline Barrientos; Diane F Jelinek; Esteban Braggio; Jose F Leis; Cong C Zhang; Steven E Coutre; Paul M Barr; Amanda F Cashen; Anthony R Mato; Avina K Singh; Michael P Mullane; Richard F Little; Harry Erba; Richard M Stone; Mark Litzow; Martin Tallman
Journal:  N Engl J Med       Date:  2019-08-01       Impact factor: 91.245

Review 4.  Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.

Authors:  Davide Rossi; Bernhard Gerber; Georg Stüssi
Journal:  Leuk Lymphoma       Date:  2016-11-03

5.  iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillermo Dighiero; Hartmut Döhner; Peter Hillmen; Michael Keating; Emili Montserrat; Nicholas Chiorazzi; Stephan Stilgenbauer; Kanti R Rai; John C Byrd; Barbara Eichhorst; Susan O'Brien; Tadeusz Robak; John F Seymour; Thomas J Kipps
Journal:  Blood       Date:  2018-03-14       Impact factor: 22.113

6.  Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Carol Moreno; Richard Greil; Fatih Demirkan; Alessandra Tedeschi; Bertrand Anz; Loree Larratt; Martin Simkovic; Olga Samoilova; Jan Novak; Dina Ben-Yehuda; Vladimir Strugov; Devinder Gill; John G Gribben; Emily Hsu; Chih-Jian Lih; Cathy Zhou; Fong Clow; Danelle F James; Lori Styles; Ian W Flinn
Journal:  Lancet Oncol       Date:  2018-12-03       Impact factor: 41.316

7.  Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.

Authors:  Rami Rahal; Mareike Frick; Rodrigo Romero; Joshua M Korn; Robert Kridel; Fong Chun Chan; Barbara Meissner; Hyo-eun Bhang; Dave Ruddy; Audrey Kauffmann; Ali Farsidjani; Adnan Derti; Daniel Rakiec; Tara Naylor; Estelle Pfister; Steve Kovats; Sunkyu Kim; Kerstin Dietze; Bernd Dörken; Christian Steidl; Alexandar Tzankov; Michael Hummel; John Monahan; Michael P Morrissey; Christine Fritsch; William R Sellers; Vesselina G Cooke; Randy D Gascoyne; Georg Lenz; Frank Stegmeier
Journal:  Nat Med       Date:  2013-12-22       Impact factor: 53.440

8.  Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.

Authors:  Eugen Tausch; Christof Schneider; Sandra Robrecht; Can Zhang; Anna Dolnik; Johannes Bloehdorn; Jasmin Bahlo; Othman Al-Sawaf; Matthias Ritgen; Anna-Maria Fink; Barbara Eichhorst; Karl-Anton Kreuzer; Maneesh Tandon; Kathryn Humphrey; Yanwen Jiang; William Schary; Lars Bullinger; Daniel Mertens; Michele Porro Lurà; Michael Kneba; Hartmut Döhner; Kirsten Fischer; Michael Hallek; Stephan Stilgenbauer
Journal:  Blood       Date:  2020-06-25       Impact factor: 22.113

9.  Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.

Authors:  Fary Diop; Riccardo Moia; Chiara Favini; Elisa Spaccarotella; Lorenzo De Paoli; Alessio Bruscaggin; Valeria Spina; Lodovico Terzi-di-Bergamo; Francesca Arruga; Chiara Tarantelli; Clara Deambrogi; Silvia Rasi; Ramesh Adhinaveni; Andrea Patriarca; Simone Favini; Sruthi Sagiraju; Clive Jabangwe; Ahad A Kodipad; Denise Peroni; Francesca R Mauro; Ilaria Del Giudice; Francesco Forconi; Agostino Cortelezzi; Francesco Zaja; Riccardo Bomben; Francesca Maria Rossi; Carlo Visco; Annalisa Chiarenza; Gian Matteo Rigolin; Roberto Marasca; Marta Coscia; Omar Perbellini; Alessandra Tedeschi; Luca Laurenti; Marina Motta; David Donaldson; Phil Weir; Ken Mills; Patrick Thornton; Sarah Lawless; Francesco Bertoni; Giovanni Del Poeta; Antonio Cuneo; Antonia Follenzi; Valter Gattei; Renzo Luciano Boldorini; Mark Catherwood; Silvia Deaglio; Robin Foà; Gianluca Gaidano; Davide Rossi
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.